NEW YORK, July 27, 2026 /PRNewswire/ — Sharon AI Holdings Inc. (NASDAQ: SHAZ) and its subsidiaries ("Sharon AI"), a leading Australian Neocloud, will release its second quarter 2026 financial results after the market closes on Thursday, August 6, 2026, followed by a conference call and webcast to discuss the results.

Sharon AI (NASDAQ: SHAZ)
Sharon AI (NASDAQ: SHAZ)

Conference Call and Webcast Details

Date & Time: Thursday, August 6, 2026, 4:30 p.m. ET
Webcast: Use this link
U.S. Dial-in: 888-506-0062
International Dial-in: 973-528-0011
Conference ID: 376509

A replay of the webcast will be available at sharonai.com/investors following the event.

About Sharon AI

Sharon AI is a leading Australian Neocloud delivering high-performance computing infrastructure for artificial intelligence workloads. Through its AI Cloud platform and GPU/CPU compute infrastructure, Sharon AI is accelerating the build of AI factories and sovereign AI solutions. For more information, visit www.sharonai.com.

Disclosure Information

Sharon AI primarily uses its Investor Relations page (https://sharonai.com/investors/) to disclose material non-public information and to comply with its disclosure obligations under Regulation FD. The Company also notes that, at times, it uses other communication mediums including, but not limited to, its X account (sharon__ai) and/or LinkedIn account (sharon-AI) to disseminate information about the Company, and can be additional sources of information outside press releases, regulatory filings with the SEC and any other conference calls, webcasts, investor days, etc. that the company may hold.

Contacts

Media
media@sharonai.com

Investors
investors@sharonai.com

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Radancy Extends AI Platform, Powering Faster, Smarter, More Cost-Efficient Hiring at Scale

NEW YORK, Sept. 9, 2025 /PRNewswire/ — Radancy, the global leader in…

Third Indication for Kelun-Biotech's TROP2 ADC Sac-TMT Approved for Marketing by NMPA in EGFRm NSCLC Following Progression on EGFR-TKI Therapy

CHENGDU, China, Oct. 11, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that…

Revelio Labs Acquires Salary Board to Expand Global Compensation Analytics

NEW YORK and SINGAPORE, May 2, 2025 /PRNewswire/ — Revelio Labs, the…